SynthesisPloS one2018
Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis.
Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic prediction byFrontiers in oncology · 2023Pooled it
- The Diagnostic Performance of Maximum Uptake Value and Apparent Diffusion Coefficient in Differentiating Benign and Malignant Ovarian or Adnexal Masses: A Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Current status and quality of radiomics studies in lymphoma: a systematic review.European radiology · 2020Pooled it
- A Lesion-adaptive Segmentation Approach for Tumor Delineation on FDG PET/CT in Diffuse Large B-cell Lymphoma Patients.European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic value of the pre-treatment SUVmax ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Metabolic parameter of baseline 18 F-FDG PET/CT with PINK models improve the prediction of treatment outcome in extranodal NK/T-cell lymphoma treated with P-GEMOX chemotherapy.Annals of hematology · 2025Article
- Appropriate timing to perform an interimAnnals of hematology · 2024Article
- Optimizing the prognostic capacity of baselineHeliyon · 2024Article
- Prognostic Value ofKorean journal of radiology · 2024Article
- Review
- Multimodality imaging evaluation of primary testicular extranodal natural killer/T-cell lymphoma: two case reports.Frontiers in medicine · 2023Article
- Article
- Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma.Life (Basel, Switzerland) · 2021Review
- Regional Brain Glucose Metabolism and Its Prognostic Value in Pretreatment Extranodal Natural Killer/T-Cell Lymphoma Patients.OncoTargets and therapy · 2021Article
- Development and validation of anEuropean radiology · 2020Article
- Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma.Medicine · 2020Article
- Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Comparison of Nasopharyngeal MR,Frontiers in oncology · 2020Article
- Prognostic Values of BaselineBioMed research international · 2020Article
- The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma.Cancer cell international · 2019Review
Corrections and comments
- Expression of concern
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
methodsWe searched the PubMed, EMBASE, Cochrane Library and Medline databases for eligible articles. SUVmax, MTV, and TLG on B-PET/CT, DS on I-PET/CT and DS on E-PET/CT were regarded as efficacy data. Combined hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were estimated using RevMan 5.3 software.
resultsNine trials with a total of 535 ENKTL patients were included. SUVmax, MTV and TLG on B-PET/CT were significantly associated with PFS with HRs of 2.78 (95%CI 1.54-5.03), 3.61 (95%CI 1.96-6.65) and 5.62 (95%CI 1.94-16.33), respectively, and with OS with HRs of 4.78 (95%CI 2.29-9.96), 3.20 (95%CI 1.55-6.60) and 7.76 (95%CI 1.79-33.58), respectively. For the DS on I-PET/CT, the HRs for PFS and OS were 5.15 (95%CI 2.71-9.80) and 5.80 (95%CI 2.28-14.73), respectively. Similarly, the DS on E-PET/CT was a significant predictor of PFS and OS with HRs of 3.65 (95%CI 2.13-6.26) and 3.32 (95%CI 1.79-6.15), respectively.
conclusionOur results suggest that SUVmax, MTV, TLG on B-PET/CT, DS on I-PET/CT and DS on E-PET/CT may be significant prognostic indicators for PFS and OS in ENKTL patients. Moreover, TLG tends to be superior to SUVmax and MTV on B-PET/CT for predicting survival of ENKTL patients. Therefore, response monitoring and prognostication assessments based on multiple PET/CT parameters should be considered in the management of ENKTL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.